ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Total neoadjuvant therapy with dose-escalated radiotherapy for organ preservation in locally advanced rectal cancer: real-world outcomes.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the role of total neoadjuvant therapy (TNT) in locally advanced rectal cancer, focusing on its impact on compliance, tumor downstaging, and organ preservation when combined with watch-and-wait (W&W) protocols and to assess whether radiotherapy dose escalation may increase clinical complete response (cCR) rates.
methodsWe retrospectively analyzed 135 patients with locally advanced rectal cancer treated with TNT and radiotherapy dose escalation (57.5 Gy to the tumor and nodes in 23 fractions) between 2015 and 2024. Patients achieving cCR were considered for the W&W strategy. Outcomes included tumor response, local control, disease-free survival (DFS), and toxicity. Prognostic factors were explored through univariate and multivariate analyses.
resultsA total of 48.9% achieved cCR and were managed nonoperatively, while 51.1% underwent surgery. Local control at 3 years was 83.5%, with local regrowth significantly higher in the W&W group (33.1%) than the rate of local recurrences in the surgical cohort (6.5%, p = 0.001). Poorer local control was associated with low rectal tumors, local regrowth, and the development of metachronous metastases. Disease-free survival at 3 years was 69.2%, with better outcomes in patients who underwent surgery or were included in the W&W strategy based on multidisciplinary consensus. No acute or chronic radiotherapy-related toxicity greater than grade 3 was observed. In multivariate analysis, local regrowth and nonconsensual W&W inclusion remained independent predictors of impaired DFS and metastasis-free survival.
conclusionTotal neoadjuvant therapy with radiotherapy dose escalation is effective and well tolerated. Tumor location, local regrowth, and the role of multidisciplinary decision-making are critical prognostic factors. Careful patient selection and structured follow-up are essential to optimize outcomes in the W&W strategy. Although functional and quality of life outcomes were not assessed, future prospective studies should incorporate these measures to further strengthen organ-preservation approaches.
Indexed as
Identifiers
42012681What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.